Advertisement
Screener

ANAPTYSBIO, INC. (ANAB) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

ANAPTYSBIO, INC. Cash Flow Breakdown

Cash flow breakdown shows where ANAPTYSBIO, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $19.70M came in.
  • Fiscal year ended 2025-12-31: from investing, $228.03M came in.
  • Fiscal year ended 2025-12-31: from financing, $132.61M went out.
  • Fiscal year ended 2025-12-31: change in cash, $115.12M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksStaff share taxNew shares soldNot split outChange in cash
2025-12-31$19.70M$228.03M-$68.63M-$1.45M$14.26M-$76.80M*$115.12M
2024-12-31-$135.34M$31.36M-$456.00K-$7.50M$6.47M$128.54M*$23.08M
2023-12-31-$120.80M$144.75M-$50.00M$0.00$2.47M-$11.77M*-$35.34M
2022-12-31-$73.59M-$394.85M$0.00$0.00$11.83M$32.19M*-$424.42M
2021-12-31-$45.92M$38.84M$0.00$2.55M$249.75M*$245.21M
2020-12-31-$14.16M$94.47M$496.00K-$1.38M*$79.44M
2019-12-31-$69.52M$131.43M$3.01M-$7.50M*$57.42M
2018-12-31-$48.51M-$142.45M$0.00$227.48M-$4.11M*$32.41M
2017-12-31-$19.44M-$243.06M$0.00$292.54M$29.96M
2016-12-31-$9.03M-$50.00K-$1.00K$0.00$8.63M*-$452.00K
2015-12-31-$9.69M-$238.00K$0.00$0.00$39.40M*$29.47M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$26.64M*$7.56M*$0.00*$0.00*$11.35M*-$106.92M*
2026-03-31-$25.92M$34.98M$0.00$0.00$14.02M-$12.81M*$10.27M
2025-12-31$98.00M*$73.50M*-$3.38M*$0.00*$12.21M*-$51.96M*
2025-09-30-$27.36M*$47.58M*-$9.72M*$0.00*$336.00K*-$1.01M*
2025-06-30-$40.24M*$92.11M*-$51.10M*$0.00*$1.42M*-$823.00K*
2025-03-31-$10.70M$14.85M-$4.42M-$1.45M$290.00K-$23.00M*-$24.44M
2024-12-31-$66.67M*-$93.43M*-$456.00K*$0.00*$555.00K*$27.47M*
2024-09-30-$10.09M*$58.62M*$0.00*$0.00*$4.13M*$67.10M*
2024-06-30-$21.32M*-$2.44M*$0.00*$0.00*$979.00K*$40.91M*
2024-03-31-$37.25M$68.62M$0.00-$7.50M$811.00K-$6.94M*$17.73M
2023-12-31-$34.35M*$49.18M*$0.00*$0.00*$264.00K*-$5.42M*
2023-09-30-$36.47M*$30.64M*$0.00*$0.00*$160.00K*-$3.23M*
2023-06-30-$25.41M*-$20.45M*-$12.47M*$0.00*$783.00K*-$1.80M*
2023-03-31-$24.57M$85.40M-$37.53M$0.00$1.26M*$23.25M
2022-12-31-$10.69M*$21.50M*$0.00*$3.42M*-$1.47M*
2022-09-30-$17.75M*-$32.43M*$0.00*$2.70M*$34.33M*
2022-06-30-$24.15M*-$71.00M*$0.00*$865.00K*
2022-03-31-$21.01M-$312.91M$0.00$4.84M-$329.32M
2021-12-31-$25.30M*-$66.69M*$1.59M*$249.75M*
2021-09-30-$7.01M*$10.84M*$241.00K*
2021-06-30$9.59M*$37.96M*$554.00K*
2021-03-31-$23.20M$56.73M$167.00K$33.69M
2020-12-31$37.58M*$3.60M*$126.00K*
2020-09-30-$17.01M*$4.73M*$263.00K*
2020-06-30-$19.61M*$75.39M*$71.00K*
2020-03-31-$15.11M$10.75M$36.00K-$1.38M*-$5.70M
2019-12-31-$15.80M*$4.04M*$3.01M*
2019-09-30-$22.10M*$59.86M*$454.00K*-$1.88M*
2019-06-30-$15.52M*$57.88M*$215.00K*-$1.88M*
2019-03-31-$16.10M$9.66M$574.00K-$1.88M*-$7.74M
2018-12-31-$12.29M*-$166.15M*$0.00*-$1.37M*
2018-09-30-$14.86M*$24.61M*$227.48M*-$880.00K*
2018-06-30-$8.88M*-$3.06M*$0.00*
2018-03-31-$12.48M$2.15M$0.00-$1.38M*-$11.71M
2017-12-31-$4.81M*-$153.06M*$0.00*$212.32M*
2017-09-30-$3.89M*-$495.00K*$0.00*$0.00*
2017-06-30-$2.64M*-$62.42M*$0.00*$0.00*-$938.00K*
2017-03-31-$8.10M-$27.09M$0.00$80.21M$45.52M
2016-12-31-$5.57M*-$1.00K*$0.00*$15.00K*$9.65M*
2016-09-30-$3.07M*$0.00*$0.00*$7.00K*
2016-06-30$1.67M*-$14.00K*$0.00*$0.00*
2016-03-31-$2.06M-$35.00K-$1.00K$9.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Innoviva, Inc. (INVA)United States$1.493B4.62
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74